Results 221 to 230 of about 215,570 (267)
Some of the next articles are maybe not open access.
Nursing Clinics of North America, 2023
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. The development and progression of atherosclerotic CVD are largely dependent on a multitude of modifiable and nonmodifiable risk factors. Current therapeutic strategies involve risk factor modification, especially dyslipidemia.
Jennifer, Ballard-Hernandez, James, Sall
openaire +2 more sources
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. The development and progression of atherosclerotic CVD are largely dependent on a multitude of modifiable and nonmodifiable risk factors. Current therapeutic strategies involve risk factor modification, especially dyslipidemia.
Jennifer, Ballard-Hernandez, James, Sall
openaire +2 more sources
Current Atherosclerosis Reports, 2023
This article sumarizes pathopysiological consequencies between obesity and dyslipidemia and aims to bring some practical approach.Dyslipidemia is often present in individuals with obesity and simultaneusly, many obese individuals have lipid metabolism disorders. Especially the abdominal obesity increases the cardiometabolic risk because of the presence
Barbora Nussbaumerova, Hana Rosolova
openaire +2 more sources
This article sumarizes pathopysiological consequencies between obesity and dyslipidemia and aims to bring some practical approach.Dyslipidemia is often present in individuals with obesity and simultaneusly, many obese individuals have lipid metabolism disorders. Especially the abdominal obesity increases the cardiometabolic risk because of the presence
Barbora Nussbaumerova, Hana Rosolova
openaire +2 more sources
Metabolism, 2019
Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines. However, recent evidence suggests that obesity-induced dyslipidemia is not a unique pathophysiological entity, but rather has distinct characteristics depending on many ...
Vekić, Jelena +4 more
openaire +4 more sources
Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines. However, recent evidence suggests that obesity-induced dyslipidemia is not a unique pathophysiological entity, but rather has distinct characteristics depending on many ...
Vekić, Jelena +4 more
openaire +4 more sources
Expert Review of Pharmacoeconomics & Outcomes Research, 2003
Dyslipidemia has been recognized as an important risk-factor for the development of cardiovascular disease. The current, available therapies of dyslipidemia, their effectiveness, costs, cost-effectiveness and healthcare implications are discussed. At the present time, the lipid-lowering therapies are dominated by statins.
Hanna, Zowall, Steven A, Grover
openaire +2 more sources
Dyslipidemia has been recognized as an important risk-factor for the development of cardiovascular disease. The current, available therapies of dyslipidemia, their effectiveness, costs, cost-effectiveness and healthcare implications are discussed. At the present time, the lipid-lowering therapies are dominated by statins.
Hanna, Zowall, Steven A, Grover
openaire +2 more sources
Metabolism, 2014
Diabetic dyslipidemia is characterized by elevated fasting and postprandial triglycerides, low HDL-cholesterol, elevated LDL-cholesterol and the predominance of small dense LDL particles. These lipid changes represent the major link between diabetes and the increased cardiovascular risk of diabetic patients.
Liya, Wu, Klaus G, Parhofer
openaire +2 more sources
Diabetic dyslipidemia is characterized by elevated fasting and postprandial triglycerides, low HDL-cholesterol, elevated LDL-cholesterol and the predominance of small dense LDL particles. These lipid changes represent the major link between diabetes and the increased cardiovascular risk of diabetic patients.
Liya, Wu, Klaus G, Parhofer
openaire +2 more sources
Contraception and dyslipidemia
American Journal of Obstetrics and Gynecology, 1993The risks of cardiovascular disease associated with dyslipidemia differ in women and men, being more strongly associated with triglyceride/high-density lipoprotein in middle-aged women than in men. Although the incidence of heart disease is lower in women because they live longer, over a lifetime, cardiovascular disease in women is equal to that in men,
R H, Knopp, J C, LaRosa, R T, Burkman
openaire +2 more sources
2014
Hyperlipidemia is an important public health problem with increased incidence and prevalence worldwide. Current clinical biomarkers, triglyceride, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol lack the necessary specificity and sensitivity and only increase significantly after serious dyslipidemia ...
Hua, Chen +4 more
openaire +2 more sources
Hyperlipidemia is an important public health problem with increased incidence and prevalence worldwide. Current clinical biomarkers, triglyceride, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol lack the necessary specificity and sensitivity and only increase significantly after serious dyslipidemia ...
Hua, Chen +4 more
openaire +2 more sources
Pharmacotherapy of Dyslipidemia
Cardiovascular Drugs and Therapy, 2001Reducing elevated levels of low-density-lipoprotein cholesterol (LDL-C) significantly reduces the incidence of coronary heart disease (CHD) events and mortality in hypercholesterolemic patients. CHD risk reduction is proportional to LDL-C reduction. Despite this knowledge, many physicians are not applying existing treatment guidelines to the extent ...
openaire +2 more sources
Dyslipidemias and Microcirculation
Current Pharmaceutical Design, 2018Dyslipidemia is widely accepted as one of the major risk factors in cardiovascular disease mainly due to its contribution in the pathogenesis of atherosclerosis in medium-sized and large arteries. However, it has become increasingly accepted that high-cholesterol levels can also adversely affect the microvasculature prior to the development of overt ...
Teresa, Padró +2 more
openaire +2 more sources
Endocrine Practice, 1996
To summarize recommended treatment strategies for various dyslipidemias.The basic pathways of lipoprotein metabolism are reviewed, and the potential for interventional alterations to correct specific dyslipidemias is outlined. Guidelines for treatment based on published clinical trials, including the consensus report of the National Cholesterol ...
openaire +2 more sources
To summarize recommended treatment strategies for various dyslipidemias.The basic pathways of lipoprotein metabolism are reviewed, and the potential for interventional alterations to correct specific dyslipidemias is outlined. Guidelines for treatment based on published clinical trials, including the consensus report of the National Cholesterol ...
openaire +2 more sources